1
|
Kusovschi JD, Ivanova AA, Gardner MS, McGarrah RW, Kraus WE, Kuklenyik Z, Pirkle JL, Barr JR. Confirmation of Statin and Fibrate Use from Small-Volume Archived Plasma Samples by High-Throughput LC-MS/MS Method. Int J Mol Sci 2023; 24:ijms24097931. [PMID: 37175638 PMCID: PMC10178340 DOI: 10.3390/ijms24097931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/20/2023] [Accepted: 04/22/2023] [Indexed: 05/15/2023] Open
Abstract
Designing studies for lipid-metabolism-related biomarker discovery is challenging because of the high prevalence of various statin and fibrate usage for lipid-lowering therapies. When the statin and fibrate use is determined based on self-reports, patient adherence to the prescribed statin dose regimen remains unknown. A potentially more accurate way to verify a patient's medication adherence is by direct analytical measurements. Current analytical methods are prohibitive because of the limited panel of drugs per test and large sample volume requirement that is not available from archived samples. A 4-min-long method was developed for the detection of seven statins and three fibrates using 10 µL of plasma analyzed via reverse-phase liquid chromatography and tandem mass spectrometry. The method was applied to the analysis of 941 archived plasma samples collected from patients before cardiac catheterization. When statin use was self-reported, statins were detected in 78.6% of the samples. In the case of self-reported atorvastatin use, the agreement with detection was 90.2%. However, when no statin use was reported, 42.4% of the samples had detectable levels of statins, with a similar range of concentrations as the samples from the self-reported statin users. The method is highly applicable in population studies designed for biomarker discovery or diet and lifestyle intervention studies, where the accuracy of statin or fibrate use may strongly affect the statistical evaluation of the biomarker data.
Collapse
Affiliation(s)
- Jennifer D Kusovschi
- Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
| | - Anna A Ivanova
- Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
| | - Michael S Gardner
- Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
| | - Robert W McGarrah
- Duke Molecular Physiology Institute, Duke University School of Medicine, Duke University, Durham, NC 27701, USA
| | - William E Kraus
- Duke Molecular Physiology Institute, Duke University School of Medicine, Duke University, Durham, NC 27701, USA
| | - Zsuzsanna Kuklenyik
- Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
| | - James L Pirkle
- Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
| | - John R Barr
- Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
| |
Collapse
|
2
|
Simultaneous Analysis of Atorvastatin and Rosuvastatin by LC-MS: Development, Validation, and Application of the Proposed Method to Analysis of Atorvastatin Pharmacokinetics in Pakistani Population. Pharm Chem J 2022. [DOI: 10.1007/s11094-022-02766-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
3
|
Moon SJ, Lee SE, Kwak YG, Kim MG. Validation of LC-MS/MS method for determination of rosuvastatin concentration in human blood collected by volumetric absorptive microsampling (VAMS). Transl Clin Pharmacol 2021; 29:125-134. [PMID: 34621705 PMCID: PMC8492392 DOI: 10.12793/tcp.2021.29.e13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 08/06/2021] [Accepted: 08/25/2021] [Indexed: 12/02/2022] Open
Abstract
In light of the shift toward patient-centric clinical trials, a measure of simplifying blood collection process and minimizing the volume of blood samples is on the rise. Volumetric absorptive microsampling (VAMS) is a microsampling device developed for blood sampling in non-hospital settings, which enables accurate hematocrit-independent collection of 10 or 20 µL of whole blood with a simple finger prick. In this study, liquid chromatography (LC)-tandem mass spectrometry workflow for quantification of rosuvastatin after VAMS sampling was developed and validated. The VAMS sample was stabilized by matrix drying and the optimum LC conditions and extraction methods were used to reach adequate sensitivity with lower limit of quantification verified at 1 ng/mL in 10 µL of blood. The bioanalytical method to quantify rosuvastatin from 1 to 100 ng/mL in VAMS sample was qualified by specificity, carryover, linearity, within-run and between-run reproducibility and stability. Inaccuracy was less than ± 6% and imprecision was less than 10% after analyzing the samples on 5 different days at all concentration levels. In addition, the feasibility of delivery to the analytical laboratory after home sampling during the guaranteed stability period of 10 days at room temperature was confirmed by evaluating concentration changes after VAMS sampling without adding pH buffer. Our results suggest that VAMS sampling did not have an effect on the stability of rosuvastatin, and it is a viable option for simple and accurate blood collection at home.
Collapse
Affiliation(s)
- Seol Ju Moon
- Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju 54907, Korea
| | - Seon Eui Lee
- Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju 54907, Korea
| | - Yong-Geun Kwak
- Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju 54907, Korea.,Department of Pharmacology, School of Medicine, Jeonbuk National University, Jeonju 54907, Korea
| | - Min-Gul Kim
- Center for Clinical Pharmacology and Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju 54907, Korea.,Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju 54907, Korea.,Department of Pharmacology, School of Medicine, Jeonbuk National University, Jeonju 54907, Korea
| |
Collapse
|
4
|
Patel M, Kothari C. A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study. Biomed Chromatogr 2019; 33:e4607. [PMID: 31141832 DOI: 10.1002/bmc.4607] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 05/06/2019] [Accepted: 05/16/2019] [Indexed: 11/12/2022]
Abstract
A simple, precise and accurate HPLC method was developed, optimized and validated for simultaneous determination of rosuvastatin and candesartan in rat plasma using atorvastatin as an internal standard. Solid-phase extraction was used for sample cleanup and its subsequent optimization was carried out to achieve higher extraction efficiency and to eliminate matrix effect. A quality by design approach was used, wherein three-level factorial design was applied for optimization of mobile phase composition and for assessing the effect of pH of the mobile phase using Design Expert Software. Adequate separation for both analytes was achieved with a Waters C18 column (250 × 4.6 mm, 5 μm) using acetonitrile-5 mm sodium acetate buffer (70:30, v/v; pH adjusted to 3.5 with acetic acid) as a mobile phase at a flow rate of 1.0 mL/min and wavelength of 254 nm. The calibration curves were linear over the concentration ranges 5-150 and 10-300 ng/mL for rosuvastatin (ROS) and candesartan (CAN), respectively. The validated method was successfully applied to a pharmacokinetic study in Wistar rats and the data did not reveal any evidence for a potential drug-drug interaction between ROS and CAN. This information provides evidence for clinical rational use of ROS and CAN.
Collapse
Affiliation(s)
- Misari Patel
- Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
| | - Charmy Kothari
- Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
| |
Collapse
|
5
|
Kotwal P, Magotra A, Dogra A, Sharma S, Gour A, Bhatt S, Wazir P, Singh PP, Singh G, Nandi U. Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1112:48-55. [DOI: 10.1016/j.jchromb.2019.02.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Revised: 01/27/2019] [Accepted: 02/21/2019] [Indexed: 10/27/2022]
|
6
|
Ângelo ML, Moreira FDL, Morais Ruela AL, Santos ALA, Salgado HRN, de Araújo MB. Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review. Crit Rev Anal Chem 2018. [PMID: 29533074 DOI: 10.1080/10408347.2018.1439364] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. This drug is indicated for dyslipidemias treatment and can help to decrease the level of "bad cholesterol" and can consequently reduce the development of atherosclerosis and the risk of heart diseases. ROS was developed by Astra-Zeneca and it was approved in 2003 by the FDA in the United States. In 2015, under the trade name Crestor®, it was the fourth largest selling drug in the United States with sales above $5 billion. This study presents a literature review of analytical methods for the quantification of ROS in pharmaceutical preparations and biological fluids. The major analytical methods described in this study for ROS were spectrophotometry, high-performance liquid chromatography (HPLC) coupled to ultraviolet (UV) detection, and tandem mass spectrometry (LC-MS/MS).
Collapse
Affiliation(s)
- Marilene Lopes Ângelo
- a Faculty of Pharmaceutical Sciences, Federal University of Alfenas , Alfenas , Minas Gerais , Brazil
| | - Fernanda de Lima Moreira
- b School of Pharmaceutical Sciences of Ribeirão Preto, São Paulo University , Ribeirão Preto , São Paulo , Brazil
| | - André Luís Morais Ruela
- c Multidisciplinary Health Institute, Federal University of Bahia , Vitória da Conquista , Bahia , Brazil
| | | | | | - Magali Benjamim de Araújo
- a Faculty of Pharmaceutical Sciences, Federal University of Alfenas , Alfenas , Minas Gerais , Brazil
| |
Collapse
|
7
|
Bhadoriya A, Sanyal M, Shah PA, Shrivastav PS. Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. Biomed Chromatogr 2018; 32:e4291. [DOI: 10.1002/bmc.4291] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Revised: 04/21/2018] [Accepted: 05/10/2018] [Indexed: 01/15/2023]
Affiliation(s)
| | - Mallika Sanyal
- Department of Chemistry; St. Xavier's College; Ahmedabad India
| | - Priyanka A. Shah
- Department of Chemistry, School of Sciences; Gujarat University; Ahmedabad India
| | - Pranav S. Shrivastav
- Department of Chemistry, School of Sciences; Gujarat University; Ahmedabad India
| |
Collapse
|
8
|
Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies. J Pharm Sci 2018; 107:1973-1986. [PMID: 29548977 DOI: 10.1016/j.xphs.2018.02.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Revised: 02/02/2018] [Accepted: 02/14/2018] [Indexed: 11/23/2022]
Abstract
Methodology for analysis of a microdosing drug cocktail designed to evaluate the contribution of drug transporters and drug metabolizing enzymes to disposition was developed using liquid chromatography-mass spectrometry-based detection. Fast and sensitive methods were developed and qualified for the quantification of statins (pitavastatin, pitavastain lactone, rosuvastatin, atorvastatin, 2-hydroxy, and 4-hydroxy atorvastatin), midazolam, and dabigatran in human plasma. Chromatographic separation was accomplished using reversed-phase liquid chromatography or hydrophilic interaction liquid chromatography with gradient elution and detection by tandem mass spectrometry in the positive ionization mode using electrospray ionization. The lower limit of quantitation (LLOQ) for the statins assay was 1 pg/mL for the 6 analytes with a linear range from 1 to 1000 pg/mL processing 250 μL plasma sample. The midazolam assay LLOQ was 0.5 pg/mL with a linear range of 0.5 to 1000 pg/mL. For the dabigatran assay, the LLOQ was 10 pg/mL with a linear range of 10 to 5000 pg/mL processing 100 μL plasma sample. The intraday and interday precision and accuracy of the assays were within acceptable ranges, and the assays were successfully applied to support a study where a microdose cocktail was dosed to healthy human subjects for simultaneous assessment of clinical drug-drug interactions mediated by major drug transporters and CYP3A.
Collapse
|
9
|
Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. J Cardiovasc Pharmacol 2017; 68:383-390. [PMID: 27557342 DOI: 10.1097/fjc.0000000000000426] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The nuclear receptors (NR)-farnesoid X receptor (FXR, NR1H4) and pregnane X receptor (PXR, NR1I2)-have important effects on the expression of genes related to the pharmacokinetics (PKs) of rosuvastatin. This study was designed to investigate whether the genetic variants in drug disposition genes (SLCO1B1 and ABCG2) combined with their upstream regulators (NR1H4 and NR1I2) would affect the PKs of rosuvastatin in a Chinese population. Sixty-one healthy male volunteers were enrolled and the plasma concentrations of rosuvastatin were measured using the liquid chromatographic-tandem mass spectrometry/MS method. All subjects were analyzed and grouped according to the genotypes of NR1H4, NR1I2, SLCO1B1, and ABCG2. The exposure of rosuvastatin was higher in subjects carrying the SLCO1B1 521C or ABCG2 421A allele compared with noncarriers. No association was observed of single-nucleotide polymorphisms in NR1H4 or NR1I2 genes with the PKs of rosuvastatin. After adjusting for the 421C>A and 521T>C variants, the Cmax in subjects with NR1I2 63396TT wild type were about 2-fold of those of NR1I2 mutant type (63396CC and CT) (10.7 vs. 20.4 ng/mL, P = 0.023), whereas no significant differences were observed for other parameters. Polymorphisms investigated in the genes of NR1H4 and NR1I2 seemed to play no significant role in the disposition of rosuvastatin.
Collapse
|
10
|
Magotra A, Sharma A, Gupta AP, Wazir P, Sharma S, Singh PP, Tikoo MK, Vishwakarma RA, Singh G, Nandi U. Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. J Chromatogr B Analyt Technol Biomed Life Sci 2017. [PMID: 28623772 DOI: 10.1016/j.jchromb.2017.06.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
In the present study, a simple, sensitive, specific and rapid liquid chromatography (LC) tandem mass spectrometry (MS/MS) method was developed and validated according to the Food and Drug Administration (FDA) guidelines for estimation of IIIM-MCD-211 (a potent oral candidate with promising action against tuberculosis) in mice plasma using carbamazepine as internal standard (IS). Bioanalytical method consisted of one step protein precipitation for sample preparation followed by quantitation in LC-MS/MS using positive electrospray ionization technique (ESI) operating in multiple reaction monitoring (MRM) mode. Elution was achieved in gradient mode on High Resolution Chromolith RP-18e column with mobile phase comprised of acetonitrile and 0.1% (v/v) formic acid in water at the flow rate of 0.4mL/min. Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively. All validation parameters were well within the limit of acceptance criteria. The method was successfully applied to assess the pharmacokinetics of the candidate in mice following oral (10mg/kg) and intravenous (IV; 2.5mg/kg) administration. It was also effectively used to quantitate metabolic stability of the compound in mouse liver microsomes (MLM) and human liver microsomes (HLM) followed by its in-vitro-in-vivo extrapolation.
Collapse
Affiliation(s)
- Asmita Magotra
- PK-PD, Toxicology and Formulation division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India; Academy of Scientific and Innovative Research (AcSIR), CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India
| | - Anjna Sharma
- PK-PD, Toxicology and Formulation division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India; Academy of Scientific and Innovative Research (AcSIR), CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India
| | - Ajai Prakash Gupta
- Quality Control and Quality Analysis Division, CSIR- Indian Institute of Integrative Medicine, Jammu, J&K, 180 001, India
| | - Priya Wazir
- PK-PD, Toxicology and Formulation division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India
| | - Shweta Sharma
- Medicinal Chemistry Division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India
| | - Parvinder Pal Singh
- Medicinal Chemistry Division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India
| | - Manoj Kumar Tikoo
- PK-PD, Toxicology and Formulation division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India
| | - Ram A Vishwakarma
- Director, CSIR-Indian Institute of Integrative Medicine, anal Road, Jammu 180001, J&K, India
| | - Gurdarshan Singh
- PK-PD, Toxicology and Formulation division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India.
| | - Utpal Nandi
- PK-PD, Toxicology and Formulation division, CSIR- Indian Institute of Integrative Medicine, Jammu 180 001, India.
| |
Collapse
|
11
|
Preparation and optimization of tablets containing a self-nano-emulsifying drug delivery system loaded with rosuvastatin. J Liposome Res 2017; 28:149-160. [DOI: 10.1080/08982104.2017.1295990] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
12
|
Wei X, Li P, Liu M, Du Y, Wang M, Zhang J, Wang J, Liu H, Liu X. Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr 2016; 31. [DOI: 10.1002/bmc.3832] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 08/23/2016] [Accepted: 08/29/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Xudan Wei
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| | - Ping Li
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd; Lianyungang China
| | - Meina Liu
- Dalian Huirui Pharmaceutical Co. Ltd; Dalian China
| | - Yuqian Du
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| | - Menglin Wang
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| | - Jinling Zhang
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| | - Jing Wang
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| | - Hongzhuo Liu
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| | - Xiaohong Liu
- Department of Biopharmaceutics, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang China
| |
Collapse
|
13
|
Arafat T, Arafat B, Abu Awwad A, Schmitz OJ. Determination of Fenofibric Acid in Human Plasma by LC–MS/MS and LC–UV. Chromatographia 2016. [DOI: 10.1007/s10337-016-3080-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Alamri RG, Mohsin K, Ahmad A, Raish M, Alanazi FK. Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics. Saudi Pharm J 2016; 25:128-135. [PMID: 28223873 PMCID: PMC5310137 DOI: 10.1016/j.jsps.2016.05.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 05/19/2016] [Indexed: 11/26/2022] Open
Abstract
A simple, precise, selective and fast ultra-high performance liquid chromatography (UHPLC-UV) method has been developed and validated for the simultaneous determination of a lipid regulating agent fenofibrate and its metabolite fenofibric acid in rat plasma. The chromatographic separation was carried out on a reversed-phase Acquity® BEH C18 column using methanol–water (65:35, v/v) as the mobile phase. The isocratic flow was 0.3 ml/min with rapid run time of 2.5 min and UV detection was at 284 nm. The method was validated over a concentration range of 100–10000 ng/ml (r2 ⩾ 0.9993). The selectivity, specificity, recovery, accuracy and precision were validated for determination of fenofibrate/fenofibric acid in rat plasma. The lower limits of detection and quantitation of the method were 30 and 90 ng/ml for fenofibrate and 40 and 100 ng/ml for fenofibric acid, respectively. The within and between-day coefficients of variation were less than 5%. The validated method has been successfully applied to measure the plasma concentrations in pharmacokinetics study of fenofibrate in an animal model to illustrate the scope and application of the method.
Collapse
Affiliation(s)
- Rayan G Alamri
- Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Kazi Mohsin
- Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Ajaz Ahmad
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Mohammad Raish
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Fars K Alanazi
- Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| |
Collapse
|
15
|
Goss GD, Jonker DJ, Laurie SA, Weberpals JI, Oza AM, Spaans JN, la Porte C, Dimitroulakos J. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J Transl Med 2016; 14:83. [PMID: 27036206 PMCID: PMC4815068 DOI: 10.1186/s12967-016-0836-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Accepted: 03/15/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical models across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity of escalating doses of rosuvastatin in combination with the standard clinical dose of erlotinib in heavily pretreated patients with advanced solid tumours. METHODS This was a single-center, phase I open-label study to determine the safety and recommended phase two dose (RPTD) of rosuvastatin in combination with 150 mg/day standard dose of erlotinib. Using a 3 + 3 study design and 28-day cycle, escalating doses of rosuvastatin from 1 to 8 mg/kg/day × 2 weeks (cycle 1) and 3 weeks (subsequent cycles) given concurrently with erlotinib were evaluated. In order to expand the experience and to gain additional safety and pharmacokinetic data, two expansions cohorts using concurrent or alternating weekly dosing regimens at the RPTD were also evaluated. RESULTS All 24 patients enrolled were evaluable for toxicity, and 22 for response. The dose-limiting toxicity (DLT) of reversible muscle toxicity was seen at the 2 mg/kg/day dose level. Maximal tolerated dose (MTD) was determined to be 1 mg/kg/day. Thirty-three percent of patients developed at least 1 ≥ grade 2 muscle toxicity (rhabdomyolysis: 1/24, myalgia: 7/24) resulting in one study-related death. Durable stable disease for more than 170 days was seen in 25 % of patients that received concurrent treatment and were evaluable for response (n = 16). Plasma erlotinib levels on study were unaffected by the addition of rosuvastatin. CONCLUSIONS The observed disease stabilization rate of 25 % with combination therapy in this heavily pretreated population is encouraging, however, the high levels of muscle toxicities observed limited this combination strategy.
Collapse
Affiliation(s)
- Glenwood D Goss
- Ottawa Hospital Research Institute, Centre for Cancer Therapeutics, Ottawa, Canada. .,The Ottawa Hospital Cancer Centre, Ottawa, Canada. .,Department of Medicine, University of Ottawa, Ottawa, Canada.
| | - Derek J Jonker
- The Ottawa Hospital Cancer Centre, Ottawa, Canada.,Department of Medicine, University of Ottawa, Ottawa, Canada
| | - Scott A Laurie
- The Ottawa Hospital Cancer Centre, Ottawa, Canada.,Department of Medicine, University of Ottawa, Ottawa, Canada
| | - Johanne I Weberpals
- Ottawa Hospital Research Institute, Centre for Cancer Therapeutics, Ottawa, Canada.,Division of Gynecologic Oncology, The Ottawa Hospital, Ottawa, Canada
| | - Amit M Oza
- University Health Network, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada
| | - Johanna N Spaans
- Ottawa Hospital Research Institute, Centre for Cancer Therapeutics, Ottawa, Canada
| | - Charles la Porte
- Ottawa Hospital Research Institute, Centre for Cancer Therapeutics, Ottawa, Canada
| | - Jim Dimitroulakos
- Ottawa Hospital Research Institute, Centre for Cancer Therapeutics, Ottawa, Canada. .,The Ottawa Hospital Cancer Centre, Ottawa, Canada. .,Faculty of Medicine and the Department of Biochemistry, University of Ottawa, Ottawa, Canada.
| |
Collapse
|
16
|
Kumar PP, Murthy TEGK, Basaveswara Rao MV. Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. J Adv Pharm Technol Res 2015; 6:118-24. [PMID: 26317076 PMCID: PMC4542398 DOI: 10.4103/2231-4040.157982] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
A new, simple and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of rosuvastatin (ROS) and metformin (MET) in human plasma was developed. The assay procedure involved simple protein precipitation with acetonitrile. Following precipitation, fraction of supernatant was decanted and evaporated under gentle stream of nitrogen at 40°C. The residue was reconstituted in mobile phase and injected. The chromatographic separation was achieved with Thermo Hypurity C18 column (50 mm × 4.6 mm, 5 μ) using a mobile phase composition containing 0.1% v/v formic acid in water and acetonitrile (30:70, v/v) at a flow rate of 0.4 mL/min. The total run time was 3.5 min. The method showed good linearity in the range 0.5–200 ng/mL for ROS and 2–2000 ng/mL for MET with correlation coefficient (r) >0.9994 for both the analytes. The intra and inter-day precision values for ROS and MET met the acceptance criteria as per regulatory guidelines. The battery of stability studies viz., bench-top, freeze-thaw and long term stability were performed. The developed method was applied to a pharmacokinetic study.
Collapse
Affiliation(s)
- P Pavan Kumar
- Department of Pharmaceutical Sciences, Krishna University, Machilipatnam, India
| | - T E G K Murthy
- Department of Pharmaceutics, Bapatla College of Pharmacy, Bapatla, Guntur, Andhra Pradesh, India
| | - M V Basaveswara Rao
- Department of Pharmaceutical Sciences, Krishna University, Machilipatnam, India
| |
Collapse
|
17
|
Tutorial review on validation of liquid chromatography–mass spectrometry methods: Part II. Anal Chim Acta 2015; 870:8-28. [DOI: 10.1016/j.aca.2015.02.016] [Citation(s) in RCA: 154] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Accepted: 02/09/2015] [Indexed: 11/17/2022]
|
18
|
Shah Y, Iqbal Z, Ahmad L, Nazir S, Watson DG, Khuda F, Khan A, Khan MI, Khan A, Nasir F. Determination of Rosuvastatin and its Metabolite N-Desmethyl Rosuvastatin in Human Plasma by Liquid Chromatography–High Resolution Mass Spectrometry: Method Development, Validation, and Application to Pharmacokinetic Study. J LIQ CHROMATOGR R T 2015. [DOI: 10.1080/10826076.2014.982866] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Yasar Shah
- Department of Pharmacy, University of Swabi, Swabi, Pakistan
| | - Zafar Iqbal
- Department of Pharmacy, University of Peshawar, Peshawar, Pakistan
| | - Lateef Ahmad
- Department of Pharmacy, University of Swabi, Swabi, Pakistan
| | - Shabnam Nazir
- Department of Pharmacy, Kohat University of Science and Technology, Pakistan
| | - David G. Watson
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
| | - Fazli Khuda
- Department of Pharmacy, University of Peshawar, Peshawar, Pakistan
| | - Abad Khan
- Department of Pharmacy, University of Swabi, Swabi, Pakistan
| | | | - Abbas Khan
- Department of Pharmacy, University of Peshawar, Peshawar, Pakistan
| | - Fazli Nasir
- Department of Pharmacy, University of Peshawar, Peshawar, Pakistan
| |
Collapse
|
19
|
Mostafa NM, Badawey AM, Lamie NT, Abd El-Aleem AEAB. SELECTIVE CHROMATOGRAPHIC METHODS FOR THE DETERMINATION OF ROSUVASTATIN CALCIUM IN THE PRESENCE OF ITS ACID DEGRADATION PRODUCTS. J LIQ CHROMATOGR R T 2014. [DOI: 10.1080/10826076.2013.828305] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Nadia M. Mostafa
- a Analytical Chemistry Department , Faculty of Pharmacy, Cairo University , Cairo , Egypt
| | - Amr M. Badawey
- a Analytical Chemistry Department , Faculty of Pharmacy, Cairo University , Cairo , Egypt
| | - Nesrine T. Lamie
- a Analytical Chemistry Department , Faculty of Pharmacy, Cairo University , Cairo , Egypt
| | | |
Collapse
|
20
|
Patel H, Rathod R, Dash RP, Nivsarkar M. SIMULTANEOUS QUANTIFICATION OF ROSUVASTATIN AND FENOFIBRIC ACID BY HPLC-UV IN RAT PLASMA AND ITS APPLICATION TO PHARMACOKINETIC STUDY. J LIQ CHROMATOGR R T 2014. [DOI: 10.1080/10826076.2013.807462] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Hitesh Patel
- a Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research-Ahmedabad, Thaltej , Ahmedabad , Gujarat , India
| | - Rajeshwari Rathod
- b Department of Pharmaceutical Analysis , B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej , Ahmedabad , Gujarat , India
| | - Ranjeet Prasad Dash
- c Department of Pharmacology and Toxicology , B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej , Ahmedabad , Gujarat , India
| | - Manish Nivsarkar
- c Department of Pharmacology and Toxicology , B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej , Ahmedabad , Gujarat , India
| |
Collapse
|
21
|
Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia. J Cereb Blood Flow Metab 2014; 34:542-51. [PMID: 24398933 PMCID: PMC3948136 DOI: 10.1038/jcbfm.2013.233] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Revised: 11/28/2013] [Accepted: 12/02/2013] [Indexed: 01/09/2023]
Abstract
In stroke, there is an imperative need to develop disease-modifying drugs able to (1) induce neuroprotection and vasculoprotection, (2) modulate recovery and brain plasticity, and (3) limit the short-term motor and cognitive consequences. We hypothesized that fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, could exert a beneficial effect on immediate and short-term poststroke consequences related to its pleiotropic mechanisms. Rats or mice were subjected to focal ischemia to determine the effects of acute treatment by fenofibrate on (i) motor and memory impairment, (2) both cerebral and vascular compartments, (3) inflammation, (4) neurogenesis, and (5) amyloid cascade. We show that fenofibrate administration results in both neuronal and vascular protection and prevents the short-term motor and cognitive poststroke consequences by interaction with several mechanisms. Modulation of PPAR-α generates beneficial effects in the immediate poststroke consequences by mechanisms involving the interactions between polynuclear neutrophils and the vessel wall, and microglial activation. Fenofibrate modulates mechanisms involved in neurorepair and amyloid cascade. Our results suggest that PPAR-α agonists could check the key points of a potential disease-modifying effect in stroke.
Collapse
|
22
|
Jin HE, Kim IB, Kim YC, Cho KH, Maeng HJ. Determination of cefadroxil in rat plasma and urine using LC-MS/MS and its application to pharmacokinetic and urinary excretion studies. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 947-948:103-10. [PMID: 24412692 DOI: 10.1016/j.jchromb.2013.12.027] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Revised: 12/03/2013] [Accepted: 12/21/2013] [Indexed: 10/25/2022]
Abstract
A simple, rapid, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed and validated for the determination of cefadroxil, a first-generation cephalosporin, in rat plasma and urine. Rat samples were deproteinized with methanol, and then injected into the LC-MS/MS system (electro-spray ionization, positive mode) for quantification. Drugs were separated on a Synergi™ 4 μm Polar-RP 80A column (150 mm × 2.0 mm, 4 μm) with a mixture of 0.1% formic acid and methanol (62:38, v/v) as the mobile phase at 0.2 mL/min. Detection was performed using multiple reaction-monitoring modes at m/z 364.1→208.1 (for cefadroxil) and m/z 368.1→174.2 (for cefaclor, the internal standard). Method was specific and linear over the concentration range of 10-10,000 ng/mL. Validation parameters for cefadroxil, including accuracy, precision, absolute matrix effect, and stability in rat plasma and urine, were acceptable according to the biological method validation guidelines of the FDA (2001) [16]. Cefadroxil levels in plasma up to 1440 min or 480 min and urine up to 96 h were quantifiable following oral and intravenous cefadroxil administrations to rats at a dose of 2mg/kg, each, suggesting that the method is appropriate for routine pharmacokinetic studies including urinary recovery in rats.
Collapse
Affiliation(s)
- Hyo-Eon Jin
- College of Pharmacy, Seoul National University, Seoul, Republic of Korea
| | - In-Bong Kim
- College of Pharmacy, Inje University, Gimhae, Gyeongnam, Republic of Korea
| | - Yu Chul Kim
- C&C Research Laboratories, Suwon, Gyeonggi, Republic of Korea
| | - Kwan Hyung Cho
- College of Pharmacy, Inje University, Gimhae, Gyeongnam, Republic of Korea
| | - Han-Joo Maeng
- College of Pharmacy, Inje University, Gimhae, Gyeongnam, Republic of Korea.
| |
Collapse
|
23
|
Sultana N, Arayne MS, Naveed S. Simultaneous Determination of Captopril and Statins in API, Pharmaceutical Formulations and in Human Serum by RP-HPLC. J CHIN CHEM SOC-TAIP 2013. [DOI: 10.1002/jccs.201000056] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Sultana N, Arayne MS, Iftikhar B. Simultaneous Determination of Atenolol, Rosuvastatin, Spironolactone, Glibenclamide and Naproxen Sodium in Pharmaceutical Formulations and Human Plasma by RP-HPLC. J CHIN CHEM SOC-TAIP 2013. [DOI: 10.1002/jccs.200800149] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
25
|
Braga VSM, Mancilha TP, Cassella RJ, Pacheco WF. Determination of Rosuvastatin in Urine by Spectrofluorimetry After Liquid–Liquid Extraction and Derivatization in Acidic Medium. J Fluoresc 2012; 23:49-55. [DOI: 10.1007/s10895-012-1115-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 07/30/2012] [Indexed: 10/28/2022]
|
26
|
Caglar S, Toker S. Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. J Chromatogr Sci 2012; 51:53-8. [PMID: 22718749 DOI: 10.1093/chromsci/bms105] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
For the first time, a carboxyl group derivatization assay has been developed and validated for the determination of the cholesterol-lowering drug rosuvastatin in human serum at picogram level by high-performance liquid chromatography with fluorescence detection. The assay procedure involved a simple one-step liquid-liquid extraction of rosuvastatin with lovastatin as internal standard from serum with an ethyl acetate-methyl tertiary buthyl ether (1:1) mixture. After pre-column derivatization with 9-anthryldiazomethane at room temperature for one hour, the reaction mixture was injected onto a Phenomenex, Synergi C18 column (250 × 4.6 mm, 4 µ i.d.). The analytes were separated with a mobile phase composed of acetonitrile-water in gradient elution mode and detected at λ(em) = 410 nm, exciting at 366 nm. Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively. To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.
Collapse
Affiliation(s)
- Sena Caglar
- Istanbul University, Faculty of Pharmacy, Department of Analytical Chemistry, 34116, Beyazit, Istanbul - Turkey.
| | | |
Collapse
|
27
|
A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Anal Bioanal Chem 2011; 402:1217-27. [PMID: 22108655 DOI: 10.1007/s00216-011-5548-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2011] [Revised: 10/30/2011] [Accepted: 11/01/2011] [Indexed: 10/15/2022]
Abstract
A simple and sensitive assay was developed and validated for the simultaneous quantification of rosuvastatin acid (RST), rosuvastatin-5S-lactone (RST-LAC), and N-desmethyl rosuvastatin (DM-RST), in buffered human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). All the three analytes and the corresponding deuterium-labeled (d6) internal standards were extracted from 50 μL of buffered human plasma by protein precipitation. The analytes were chromatographically separated using a Zorbax-SB Phenyl column (2.1 mm × 100 mm, 3.5 μm). The mobile phase comprised of a gradient mixture of 0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile (solvent B). The analytes were separated at baseline within 6.0 min using a flow rate of 0.35 mL/min. Mass spectrometry detection was carried out in positive electrospray ionization mode. The calibration curves for all three analytes were linear (R ≥ 0.9964, n = 3) over the concentration range of 0.1-100 ng/mL for RST and RST-LAC, and 0.5-100 ng/mL for DM-RST. Mean extraction recoveries ranged within 88.0-106%. Intra- and inter-run mean percent accuracy were within 91.8-111% and percent imprecision was ≤15%. Stability studies revealed that all the analytes were stable in matrix during bench-top (6 h on ice-water slurry), at the end of three successive freeze and thaw cycles and at -80°C for 1 month. The method was successfully applied in a clinical study to determine the concentrations of RST and the lactone metabolite over 12-h post-dose in patients who received a single dose of rosuvastatin.
Collapse
|
28
|
Wang G, Guo J, Meng F, Song X, Zhong B, Zhao Y. Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. Biomed Chromatogr 2011; 26:497-501. [DOI: 10.1002/bmc.1693] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2011] [Accepted: 07/08/2011] [Indexed: 11/09/2022]
Affiliation(s)
| | - Jifen Guo
- Beijing Institute of Pharmacology and Toxicology; 27 Taiping Road; Beijing; 100850; People's Republic of China
| | - Fanhua Meng
- Beijing Institute of Pharmacology and Toxicology; 27 Taiping Road; Beijing; 100850; People's Republic of China
| | - Xiaomei Song
- Shaanxi University of Chinese Medicine; Century Road; Xianyang; 712046; People's Republic of China
| | - Bohua Zhong
- Beijing Institute of Pharmacology and Toxicology; 27 Taiping Road; Beijing; 100850; People's Republic of China
| | - Yimin Zhao
- Beijing Institute of Pharmacology and Toxicology; 27 Taiping Road; Beijing; 100850; People's Republic of China
| |
Collapse
|
29
|
Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2011; 52:922-31. [PMID: 21712498 DOI: 10.1177/0091270011407494] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
HIV-1 protease inhibitors often cause dyslipidemia, necessitating the use of lipid-lowering agents such as rosuvastatin. However, when given concomitantly, these therapeutic agents often exhibit adverse drug interactions. In this study (phase I open-label trial, n = 12 HIV-1 seronegative participants), the authors assessed the drug interactions between darunavir/ritonavir given in combination with rosuvastatin. Participants were randomized to receive rosuvastatin (10 mg/day) or darunavir/ritonavir (600/100 mg twice daily) alone for 7 days in a crossover design followed by combination therapy for 7 days with intervening 7-day washout periods. Intensive blood sampling for pharmacokinetics and fasting lipids was performed on days 7, 21, and 35. The geometric mean AUC(0-24 h) of rosuvastatin increased from 109 to 161 ng·h/mL (P < .005) and C(max) increased 6.7 to 16.3 ng/mL (P < .001) when coadministered with darunavir/ritonavir. In the presence of darunavir/ritonavir and rosuvastatin, total cholesterol and triglyceride levels increased by 10% (P = .007) and 56% (P = .011), whereas the high-density lipoprotein cholesterol levels decreased by 13% (P = .006) relative to rosuvastatin administration alone. There were no significant adverse events attributable to the coadministration of these drugs. Rosuvastatin levels increase in the presence of darunavir/ritonavir coadministration, whereas the lipid-lowering benefits are blunted. The clinical significance of these changes requires further investigation.
Collapse
Affiliation(s)
- Divya Samineni
- James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio 45267-0004, USA
| | | | | | | |
Collapse
|
30
|
Validated Method for the Simultaneous Determination of Lisinopril, Pravastatin, Atorvastatin and Rosuvastatin in API, Formulations and Human Serum by RP-HPLC. CHINESE J CHEM 2011. [DOI: 10.1002/cjoc.201190226] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
31
|
Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, Nasir F. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: Method development, validation and optimization of various experimental parameters. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:557-63. [DOI: 10.1016/j.jchromb.2011.01.004] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2010] [Revised: 01/03/2011] [Accepted: 01/05/2011] [Indexed: 01/24/2023]
|
32
|
Munjal V, Paliwal N, Varshney B, Chaursia BK, Paliwal J. LC-MS Estimation of Fenofibric Acid in Microvolumes of Human Plasma and Its Application to Bioequivalence Study. Chromatographia 2010. [DOI: 10.1365/s10337-010-1691-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
33
|
Lee HB, Peart TE, Svoboda ML, Backus S. Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples. CHEMOSPHERE 2009; 77:1285-1291. [PMID: 19863993 DOI: 10.1016/j.chemosphere.2009.09.068] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2009] [Revised: 09/28/2009] [Accepted: 09/29/2009] [Indexed: 05/28/2023]
Abstract
Rosuvastatin (RST) and atorvastatin (ATO) are prescription drugs and members in the statin family used for the treatment of elevated cholesterol levels. A method using solid-phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the determination of ATO, RST and its metabolite rosuvastatin lactone (RSTL) in sewage and surface water samples has been developed. In the influent and effluent samples collected from 11 sewage treatment plants located in Ontario, Canada, ATO, RST, and RSTL were detected in all samples with median concentrations of 166 ng L(-1) (influent) and 77 ng L(-1) (effluent) for ATO, 448 ng L(-1) (influent) and 324 ng L(-1) (effluent) for RST, as well as 158 ng L(-1) (influent) and 41 ng L(-1) (effluent) for RSTL. Due to the inter-conversion between RST and RSTL, the total concentration of RST and RSTL in a sewage sample should be reported. The median removal rate by wastewater treatment was 66% for ATO and 22% for RST and RSTL combined. These statins were quite persistent in sewage. After a storage period of 21 and 62 days, there was only a slight decrease in ATO concentration and no change in the total RST concentrations. These three compounds were also detected in a number of surface water samples at low ng L(-1) concentrations. This is the first reported occurrence and fate of RST and RSTL in the Canadian aquatic environment.
Collapse
Affiliation(s)
- Hing-Biu Lee
- Aquatic Ecosystem Protection Research Branch, Environment Canada, 867 Lakeshore Road, Burlington, ON, Canada.
| | | | | | | |
Collapse
|
34
|
Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection. Vascul Pharmacol 2009; 51:323-30. [PMID: 19732852 DOI: 10.1016/j.vph.2009.08.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2009] [Revised: 07/24/2009] [Accepted: 08/25/2009] [Indexed: 11/23/2022]
Abstract
To explore the mechanisms of action of preventive neuroprotection induced by PPAR-alpha activation, we have evaluated the neuronal, vascular effects of preventive treatment with fenofibrate up until the induction of experimental brain ischaemia and fenofibrate treatment withdrawn 3days before ischaemia induction. Fenofibrate (200mg/kg/day) was administered in rats for 14days or withdrawn 3days before induction of cerebral ischaemia. Animals underwent a 1-hour middle cerebral artery occlusion (MCAo), followed by reperfusion for 24h. The MCA's vasoreactivity was analyzed and brain sections were used to assess infarct size, inflammatory and oxidative stress markers. Fenofibrate administration significantly decreases the cerebral infarct volume. This effect was associated with partial prevention of post-ischaemic endothelial dysfunction. However, withdrawal of the fenofibrate treatment 3days before the induction of ischaemia reduced the neuroprotection and was less beneficial in preventing endothelial dysfunction as well as superoxide anion production. In contrast, fenofibrate significantly reduced microglial activation and neutrophil infiltration into the ischaemic zone to a similar extent in both treatment modes. Our results show that the fenofibrate-induced cerebral protective effect may be related to both an acute effect and a preconditioning-like mechanism. The vascular protective effect appears rather to translate the acute effects of fenofibrate administration.
Collapse
|
35
|
Bhavesh D, Shah S, Shivprakash. Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. Biomed Chromatogr 2009; 23:922-8. [DOI: 10.1002/bmc.1203] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
36
|
Gomes FP, García PL, Porto Alves JM, Singh AK, Kedor-Hackmann ERM, Miritello Santoro MIR. Development and Validation of Stability-Indicating HPLC Methods for Quantitative Determination of Pravastatin, Fluvastatin, Atorvastatin, and Rosuvastatin in Pharmaceuticals. ANAL LETT 2009. [DOI: 10.1080/00032710903060669] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Automated liquid–liquid extraction method for high-throughput analysis of rosuvastatin in human EDTA K2 plasma by LC–MS/MS. Bioanalysis 2009; 1:529-35. [DOI: 10.4155/bio.09.47] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: Liquid–liquid extraction has been widely used for the analysis of rosuvastatin due to its many attractive features, such as low cost and clean extract. However, manual transfer of the organic phase poses a challenge, particularly when a batch size is large. To overcome the challenge, a simple automated high-throughput (192 samples per batch) liquid–liquid extraction method with short (3.0-min) chromatographic run time was proposed. Rosuvastatin was separated using a gradient on a reversed-phase C18 column and detected in the multiple reaction monitoring made with a mass transition of m/z 482.3→258.2 amu. Results: The assay exhibited a linear range from 50 to 25000 pg/ml (r ≥ 0.9976). The intra- and inter-day accuracy ranged from 98.16 to 103.84% and 101.18 to 103.95%, respectively. The intra- and inter-day precision ranged from 0.70 to 6.17% and 2.19 to 5.07%, respectively. Conclusion: Finally, the validated method was successfully applied to bioequivalence studies.
Collapse
|
38
|
Rodríguez Robledo V, Smyth WF. A study of the analytical behaviour of selected new molecular entities using electrospray ionisation ion trap mass spectrometry, liquid chromatography, gas chromatography and polarography and their determination in serum at therapeutic concentrations. Anal Chim Acta 2008; 623:221-30. [PMID: 18620927 DOI: 10.1016/j.aca.2008.06.025] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2008] [Accepted: 06/16/2008] [Indexed: 10/21/2022]
Abstract
This paper provides analytical chemical information on selected new molecular entities (NMEs) which are drugs that have recently been approved by the FDA. These are the antiretroviral drugs, atazanavir, indinavir and emtricitabine, the antibacterial gemifloxacin, rosuvastatine which is a cholesterol-lowering drug, the anti-cancer drug gefitinib and aprepitant for neurological disorders. Electrospray ionisation-quadrupole ion trap mass spectrometry (ESI-MS(n)) was employed to generate tandem mass spectrometric (MS(2)) data of the drugs studied and structural assignments of product ions were supported by quadrupole time-of-flight mass spectrometry (QToF-MS/MS). These fragmentation studies were then utilised in the development and validation of a specific and sensitive liquid chromatographic method (LC-ESI-MS(2)) to identify and determine these drugs at therapeutic concentration levels in serum after a single protein precipitation procedure with acetonitrile. In addition, this method was compared to the application of gas liquid chromatography-flame ionisation detection (GLC-FID) and differential pulse polarography (DPP) for the analysis of these NMEs in serum.
Collapse
Affiliation(s)
- Virginia Rodríguez Robledo
- Department of Analytical Chemistry and Food Technology, University of Castilla-La Mancha, Ciudad Real, Spain
| | | |
Collapse
|
39
|
Park EK, Watanabe T, Gee SJ, Schenker MB, Hammock BD. Creatinine measurements in 24 h urine by liquid chromatography--tandem Mass Spectrometry. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2008; 56:333-336. [PMID: 18092755 DOI: 10.1021/jf072433s] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
A simple, sensitive, and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determining urinary creatinine was developed and used to evaluate 24 h urine samples collected during an exposure study. Urine (1 microL) was diluted with methanol and then directly applied to LC-MS/MS. Under electrospray ionization (ESI) conditions, the transition molecules of creatinine and creatinine- d3 were observed at m/ z 114 > 44 and m/ z 117 > 47, respectively. The retention time of creatinine was 0.59 min. The linear range was 1-2000 ng/mL, with a detection limit in urine of 1 ng/mL. LC-MS/MS and colorimetric end-point methods were significantly associated ( R2 = 0.8785, p < 0.0001). The LC-MS/MS method to determine creatinine in 24 h urine samples had shorter retention times, was more sensitive, reliable, reproducible, simple, selective, and used a smaller sample size than other LC-MS/MS or commercial methods.
Collapse
Affiliation(s)
- Eun-Kee Park
- Department of Entomology and Cancer Research Center, and Department of Public Health Sciences, University of California, Davis, CA 95616, USA
| | | | | | | | | |
Collapse
|
40
|
Lan K, Jiang X, Li Y, Wang L, Zhou J, Jiang Q, Ye L. Quantitative determination of rosuvastatin in human plasma by ion pair liquid–liquid extraction using liquid chromatography with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 2007; 44:540-6. [PMID: 17289330 DOI: 10.1016/j.jpba.2006.12.022] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Revised: 12/25/2006] [Accepted: 12/28/2006] [Indexed: 11/16/2022]
Abstract
A simple and sensitive liquid chromatography/tandem mass spectrometry method was developed and validated for the quantification of rosuvastatin in human plasma. After being treated with acetic acid and tetrabutyl ammonium hydroxide, the analyte was extracted by simple one-step liquid-liquid extraction with the internal standard (IS: estrone). The chromatographic separation was performed on a Phenomenex Luna C18 column with a mobile phase consisting of 2% formic acid/methanol (20:90, v/v) at a flow rate of 1.00 mL/min with a split of 200 microL to mass spectrometer. The retention time of rosuvastatin and internal standard was 2.3 and 3.4 min, respectively. Triple-quadrupole MS/MS detection was operated in positive mode by monitoring the transition of m/z 482-->258 for rosuvastatin and m/z 271-->253 for IS. Validation results indicated that the lower limit of quantification (LLOQ) was 0.1 ng mL(-1) and the assay exhibited a linear range of 0.1-20 ng mL(-1) and gave a correlation coefficient (r) of 0.9990 or better. Inaccuracy was less than 8.4% and imprecision less than 12.8% at all tested concentration levels. The analyte was stable in human plasma following three freeze/thaw cycles and for up to 8 weeks following storage at -20 degrees C. The assay was successfully applied to the analysis of rosuvastatin in human plasma samples derived from clinical pre-trials.
Collapse
Affiliation(s)
- Ke Lan
- West China School of Pharmacy, Sichuan University, Chengdu 610041, PR China
| | | | | | | | | | | | | |
Collapse
|
41
|
Nirogi R, Mudigonda K, Kandikere V. Chromatography–mass spectrometry methods for the quantitation of statins in biological samples. J Pharm Biomed Anal 2007; 44:379-87. [PMID: 17433599 DOI: 10.1016/j.jpba.2007.02.008] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2006] [Revised: 02/06/2007] [Accepted: 02/08/2007] [Indexed: 11/29/2022]
Abstract
The 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, more commonly known as 'statins', are a novel class of drugs widely used for the treatment of hypercholesterolaemia in patients with established cardiovascular disease as well as those at high risk of developing atherosclerosis. Published chromatographic-mass spectrometric methods for the quantification of presently available seven statins, atorvastatin, simvastatin, lovastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin are reviewed. High performance liquid chromatography (HPLC) in combination with tandem mass spectrometry (MS/MS) is the analytical technique of choice for the quantification of statins in biological samples. This review envisages that most of the methods used for quantification of statins are in plasma and they are suitable for therapeutic drug monitoring of these drugs.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Biopharmaceutical Research, Suven Life Sciences Ltd., Serene Chambers, Road # 7, Banjara Hills, Hyderabad 500034, India.
| | | | | |
Collapse
|
42
|
Gao J, Zhong D, Duan X, Chen X. Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856:35-40. [PMID: 17560178 DOI: 10.1016/j.jchromb.2007.05.012] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2006] [Revised: 05/09/2007] [Accepted: 05/11/2007] [Indexed: 01/12/2023]
Abstract
A sensitive liquid chromatography/tandem mass spectrometric (LC-MS/MS) method was developed and validated for the determination of rosuvastatin in human plasma. The plasma samples were prepared using liquid-liquid extraction with ethyl ether. Chromatographic separation was accomplished on a Zorbax XDB-C18 (150 mm x 4.6 mm i.d., 5 microm) column. The mobile phase consisted of methanol-water (75:25, v/v, adjusted to pH 6 by aqueous ammonia). Detection of rosuvastatin and the internal standard (IS) hydrochlorothiazide was achieved by ESI MS/MS in the negative ion mode. The lower limit of quantification was 0.020 ng/ml by using 200 microl aliquots of plasma. The linear range of the method was from 0.020 to 60.0 ng/ml. The intra- and inter-day precisions were lower than 8.5% in terms of relative standard deviation (RSD), and the accuracy was within -0.3 to 1.9% in terms of relative error (RE). Compared with the existing methods, the validated method offered increased sensitivity. The method was successfully applied for the evaluation of pharmacokinetics of rosuvastatin after single oral doses of 5, 10 and 20 mg rosuvastatin to 10 healthy volunteers.
Collapse
Affiliation(s)
- Jun Gao
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 646 Songtao Road, Shanghai 201203, PR China
| | | | | | | |
Collapse
|
43
|
Sener E, Korkmaz OT, Yeniceli D, Dogrukol-Ak D, Tuncel M, Tuncel N. Determination of Carbamazepine and its Main Metabolite Carbamazepine-10,11-Epoxide in Rat Brain Microdialysate and Blood Using ESI–LC–MS (Ion Trap). Chromatographia 2007. [DOI: 10.1365/s10337-007-0224-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
44
|
Süslü İ, Çelebier M, Altınöz S. Determination of Rosuvastatin in Pharmaceutical Formulations by Capillary Zone Electrophoresis. Chromatographia 2007. [DOI: 10.1365/s10337-007-0221-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
45
|
Oliveira PR, Junior LB, Fronza M, Bernardi LS, Masiero SMK, Dalmora SL. Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Ezetimibe in Human Plasma and Pharmaceutical Formulations. Chromatographia 2006. [DOI: 10.1365/s10337-006-0749-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
46
|
Kumar TR, Shitut NR, Kumar PK, Vinu MCA, Kumar VVP, Mullangi R, Srinivas NR. Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomed Chromatogr 2006; 20:881-7. [PMID: 16389642 DOI: 10.1002/bmc.611] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A specific, accurate, precise and reproducible high-performance liquid chromatography (HPLC) method was developed for the estimation of rosuvastatin (RST), a novel, synthetic and potent HMG-CoA inhibitor in rat plasma. The assay procedure involved simple liquid-liquid extraction of RST and internal standard (IS, ketoprofen) from a small plasma volume directly into acetonitrile. The organic layer was separated and evaporated under a gentle stream of nitrogen at 40 degrees C. The residue was reconstituted in the mobile phase and injected onto a Kromasil KR 100-5C18 column (4.6 x 250 mm, 5 microm). Mobile phase consisting of 0.05 m formic acid and acetonitrile (55:45, v/v) was used at a flow rate of 1.0 mL/min for the effective separation of RST and IS. The detection of the analyte peak was achieved by monitoring the eluate using a UV detector set at 240 nm. The ratio of peak area of analyte to IS was used for quantification of plasma samples. Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively. The standard curve for RST was linear (r2 > 0.999) in the concentration range 0.02-10 microg/mL. Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma. The lower limit of quantification (LLOQ) of RST was 0.02 microg/mL. The inter- and intra-day precisions in the measurement of quality control (QC) samples, 0.02, 0.06, 1.6 and 8.0 microg/mL, were in the range 7.24-12.43% relative standard deviation (RSD) and 2.28-10.23% RSD, respectively. Accuracy in the measurement of QC samples was in the range 93.05-112.17% of the spiked nominal values. Both analyte and IS were stable in the battery of stability studies, viz. benchtop, autosampler and freeze-thaw cycles. RST was found to be stable for a period of 30 days on storage at -80 degrees C. The application of the assay to determine the pharmacokinetic disposition after a single oral dose to rats is described.
Collapse
Affiliation(s)
- Thammera Ranjith Kumar
- Drug Metabolism and Pharmacokinetics, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad 500 049, India
| | | | | | | | | | | | | |
Collapse
|
47
|
Vittal S, Shitut NR, Kumar TR, Vinu MCA, Mullangi R, Srinivas NR. Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomed Chromatogr 2006; 20:1252-9. [PMID: 16838266 DOI: 10.1002/bmc.692] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A simple, sensitive and specific high-performance liquid chromatography method is described for simultaneous determination of rosuvastatin (RST) and gemfibrozil (GFZ) in human plasma using celecoxib as an internal standard (IS). The assay procedure involved extraction of RST, GFZ and IS from plasma into acetonitrile. Following separation and evaporation of the organic layer the residue was reconstituted in the mobile phase and injected onto an X-Terra C(18) column (4.6 x 150 mm, 5.0 microm). The chromatographic run time was less than 20 min using flow gradient (0.0-1.60 mL/min) with a mobile phase consisting of 0.01 M ammonium acetate:acetonitrile:methanol (50:40:10, v/v/v) and UV detection at 275 nm. Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively. Absolute recovery of both analytes and IS was greater than 90%. The lower limit of quantification (LLOQ) of RST and GFZ was 0.03 and 0.30 microg/mL, respectively. Linearity was excellent (r(2) = 0.999) in the 0.03-10 microg/mL and 0.3-100 microg/mL ranges for RST and GFZ, respectively. The inter- and intra-day precisions in the measurement of RST quality control (QC) samples 0.03, 0.09, 2.50 and 8.00 microg/mL were in the range 2.37-9.78% relative standard deviation (RSD) and 0.92-10.08% RSD, respectively. Similarly, the inter- and intra-day precisions in the measurement of GFZ quality control (QC) samples 0.30, 0.90, 25.0 and 80.0 microg/mL were in the ranges 2.79-6.27 and 0.96-9.69% RSD, respectively. Accuracies in the measurement of QC samples for RST and GFZ were in the range 85.43-107.23 and 84.98-102.35% respectively, of the nominal values. RST and GFZ were stable in the array of stability studies viz., bench-top, auto-sampler and freeze-thaw cycles. Stability of RST and GFZ was established for 1 month at -80C. The application of the assay in an oral pharmacokinetic study in rats co-administered with RST and GFZ is described.
Collapse
Affiliation(s)
- Shivva Vittal
- Department of Drug Metabolism and Pharmacokinetics, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad-500 049, India
| | | | | | | | | | | |
Collapse
|
48
|
Srinivas NR. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed Chromatogr 2006; 20:383-414. [PMID: 16307470 DOI: 10.1002/bmc.594] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The development of sound bioanalytical method(s) is of paramount importance during the process of drug discovery and development culminating in a marketing approval. Although the bioanalytical procedure(s) originally developed during the discovery stage may not necessarily be fit to support the drug development scenario, they may be suitably modified and validated, as deemed necessary. Several reviews have appeared over the years describing analytical approaches including various techniques, detection systems, automation tools that are available for an effective separation, enhanced selectivity and sensitivity for quantitation of many analytes. The intention of this review is to cover various key areas where analytical method development becomes necessary during different stages of drug discovery research and development process. The key areas covered in this article with relevant case studies include: (a) simultaneous assay for parent compound and metabolites that are purported to display pharmacological activity; (b) bioanalytical procedures for determination of multiple drugs in combating a disease; (c) analytical measurement of chirality aspects in the pharmacokinetics, metabolism and biotransformation investigations; (d) drug monitoring for therapeutic benefits and/or occupational hazard; (e) analysis of drugs from complex and/or less frequently used matrices; (f) analytical determination during in vitro experiments (metabolism and permeability related) and in situ intestinal perfusion experiments; (g) determination of a major metabolite as a surrogate for the parent molecule; (h) analytical approaches for universal determination of CYP450 probe substrates and metabolites; (i) analytical applicability to prodrug evaluations-simultaneous determination of prodrug, parent and metabolites; (j) quantitative determination of parent compound and/or phase II metabolite(s) via direct or indirect approaches; (k) applicability in analysis of multiple compounds in select disease areas and/or in clinically important drug-drug interaction studies. A tabular representation of select examples of analysis is provided covering areas of separation conditions, validation aspects and applicable conclusion. A limited discussion is provided on relevant aspects of the need for developing bioanalytical procedures for speedy drug discovery and development. Additionally, some key elements such as internal standard selection, likely issues of mass detection, matrix effect, chiral aspects etc. are provided for consideration during method development.
Collapse
Affiliation(s)
- Nuggehally R Srinivas
- Drug Development, Discovery Research, Dr Reddy's Laboratories Limited, Bollaram Road, Miyapur, Hyderabad, India.
| |
Collapse
|
49
|
Xu DH, Ruan ZR, Zhou Q, Yuan H, Jiang B. Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2006; 20:2369-75. [PMID: 16841359 DOI: 10.1002/rcm.2542] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
A simple and sensitive liquid chromatography/tandem mass spectrometry method was developed and validated for determining rosuvastatin in human plasma, a new synthetic hydroxymethylglutaryl-coenzyme A reductase inhibitor. The analyte and internal standard (IS; cilostazol) were extracted by simple one-step liquid/liquid extraction with ether. The organic layer was separated and evaporated under a gentle stream of nitrogen at 40 degrees C. The chromatographic separation was performed on an Atlantis C18 column (2.1 mm x 150 mm, 5.0 microm) with a mobile phase consisting of 0.2% formic acid/methanol (30:70, v/v) at a flow rate of 0.20 mL/min. The analyses were carried out by multiple reaction monitoring (MRM) using the precursor-to-product combinations of m/z 482 --> 258 and m/z 370 --> 288. The areas of peaks from the analyte and the IS were used for quantification of rosuvastatin. The method was validated according to the FDA guidelines on bioanalytical method validation. Validation results indicated that the lower limit of quantification (LLOQ) was 0.2 ng/mL and the assay exhibited a linear range of 0.2-50.0 ng/mL and gave a correlation coefficient (r) of 0.9991 or better. Quality control samples (0.4, 8, 25 and 40 ng/mL) in six replicates from three different runs of analysis demonstrated an intra-assay precision (RSD) 7.97-15.94%, an inter-assay precision 3.19-15.27%, and an overall accuracy (relative error) of < 3.7%. The method can be applied to pharmacokinetic or bioequivalence studies of rosuvastatin.
Collapse
Affiliation(s)
- Dong-Hang Xu
- Division of Clinical Pharmacology, The Second Affiliated Hospital School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, China
| | | | | | | | | |
Collapse
|